Search

Your search keyword '"Jazaeri, Amir"' showing total 664 results

Search Constraints

Start Over You searched for: Author "Jazaeri, Amir" Remove constraint Author: "Jazaeri, Amir"
664 results on '"Jazaeri, Amir"'

Search Results

2. METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics

7. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance

8. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer

14. Immuno-Oncology for Gynecologic Malignancies

15. Feasibility of using the handheld MasSpec pen technology for intraoperative identification of ovarian cancer during tumor reductive surgery.

18. Clinical and genomic landscape of RAS mutations in gynecologic cancers

19. Immuno-oncology for Gynecologic Malignancies

26. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer

28. Abstract A077: The utility of surgical minimal residual disease after frontline treatment for prognostic and investigational opportunities in advanced ovarian cancer

29. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma

30. Phase 1b Study of Batiraxcept (AVB-S6-500) in Combination with Durvalumab (MEDI4736) in Patients with Platinum-Resistant Ovarian Cancer

31. Phase II Trial of Pembrolizumab in Combination with Chemotherapy for Frontline Treatment of Advanced Epithelial Ovarian Cancer

34. EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.

38. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer

39. 1045 Overcoming immunosuppressive tumors by stimulating the adaptive and innate immune systems

40. Transforming ovarian cancer care by targeting minimal residual disease

41. SO013/#983 Intraoperative identification of ovarian cancer during tumor reductive surgery using the hand-held masspec pen technology

42. EP159/#1534 Leveraging personalized circulating tumor DNA monitoring to predict treatment response and recurrence in high-risk endometrial cancer

44. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice

50. Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.

Catalog

Books, media, physical & digital resources